Waldenstrom Macroglobulinemia clinical trials in Massachusetts
12 active Waldenstrom Macroglobulinemia trials with a site in Massachusetts. Describe your situation to see which ones look like a fit.
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
- Epcoritamab in Previously Treated WM
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Study of SGR-1505 in Mature B-Cell Neoplasms
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Loncastuximab Tesirine in WM
- Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.